Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
โ Scribed by Zander, T.; Scheffler, M.; Nogova, L.; Kobe, C.; Engel-Riedel, W.; Hellmich, M.; Papachristou, I.; Toepelt, K.; Draube, A.; Heukamp, L.; Buettner, R.; Ko, Y. D.; Ullrich, R. T.; Smit, E.; Boellaard, R.; Lammertsma, A. A.; Hallek, M.; Jacobs, A. H.; Schlesinger, A.; Schulte, K.; Querings, S.; Stoelben, E.; Neumaier, B.; Thomas, R. K.; Dietlein, M.; Wolf, J.
- Book ID
- 117990412
- Publisher
- American Society of Clinical Oncology
- Year
- 2011
- Tongue
- English
- Weight
- 189 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0732-183X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: [f-18]fluorodeoxyglucose (fdg)-positron emission tomography (pet) can measure the metabolic activity of tissues; fdg-pet may be able to predict response to chemotherapy by identifying changes in tumor metabolism. measurement of response to treatment may help improve survival in the m